| pubmed-article:15449756 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15449756 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15449756 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:15449756 | lifeskim:mentions | umls-concept:C0360714 | lld:lifeskim |
| pubmed-article:15449756 | lifeskim:mentions | umls-concept:C0178602 | lld:lifeskim |
| pubmed-article:15449756 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:15449756 | pubmed:dateCreated | 2004-9-28 | lld:pubmed |
| pubmed-article:15449756 | pubmed:abstractText | The Pravastatin or Atorvastatin Evaluation and Infection Therapy trial (PROVE-IT/TIMI-22) showed that in patients with acute coronary syndromes, aggressive lipid-lowering using atorvastatin 80 mg/day provided greater protection against death or major cardiovascular events than did moderate lipid-lowering using pravastatin 40 mg/day. Lowering the low-density lipoprotein cholesterol level to approximately 62 mg/dL with atorvastatin resulted in a 16% reduction in cardiovascular end points. | lld:pubmed |
| pubmed-article:15449756 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15449756 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15449756 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15449756 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15449756 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15449756 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15449756 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15449756 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:15449756 | pubmed:issn | 0891-1150 | lld:pubmed |
| pubmed-article:15449756 | pubmed:author | pubmed-author:WatersDavidD | lld:pubmed |
| pubmed-article:15449756 | pubmed:author | pubmed-author:KhushKiran... | lld:pubmed |
| pubmed-article:15449756 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15449756 | pubmed:volume | 71 | lld:pubmed |
| pubmed-article:15449756 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15449756 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15449756 | pubmed:pagination | 609-16 | lld:pubmed |
| pubmed-article:15449756 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:meshHeading | pubmed-meshheading:15449756... | lld:pubmed |
| pubmed-article:15449756 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15449756 | pubmed:articleTitle | Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients. | lld:pubmed |
| pubmed-article:15449756 | pubmed:affiliation | Division of Cardiology, Department of Medicine, University of California, San Francisco 94143, USA. kkhush@medicine.ucsf.edu | lld:pubmed |
| pubmed-article:15449756 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15449756 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
